Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 randomized, controlled clinical trial of AB-SA01 in patients with a hip or knee prosthetic joint infection due to S. aureus as an adjunct to surgical treatment

Trial Profile

A Phase 1/2 randomized, controlled clinical trial of AB-SA01 in patients with a hip or knee prosthetic joint infection due to S. aureus as an adjunct to surgical treatment

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AP SA01 (Primary) ; AP SA01 (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 May 2019 According to an Armata Pharmaceuticals media release, IND application for Staphylococcus aureus bacteremia is planned for 2019.
    • 09 May 2019 C3J Therapeutics and AmpliPhi Biosciences have merged together and formed Armata Pharmaceuticals, Inc.
    • 27 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top